mitoxantrone has been researched along with Exanthema in 5 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Exanthema: Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Debord, C | 1 |
| Grain, A | 1 |
| Theisen, O | 1 |
| Boutault, R | 1 |
| Rialland, F | 1 |
| Eveillard, M | 1 |
| Wan Ariffin, E | 1 |
| Jones, H | 1 |
| Bhatnagar, N | 1 |
| Fleming, MT | 1 |
| Sonpavde, G | 1 |
| Kolodziej, M | 1 |
| Awasthi, S | 1 |
| Hutson, TE | 1 |
| Martincic, D | 1 |
| Rastogi, A | 1 |
| Rousey, SR | 1 |
| Weinstein, RE | 1 |
| Galsky, MD | 1 |
| Berry, WR | 1 |
| Wang, Y | 1 |
| Boehm, KA | 1 |
| Asmar, L | 1 |
| Rauch, MA | 1 |
| Beer, TM | 1 |
| Glossmann, JP | 1 |
| Staak, JO | 1 |
| Wickenhauser, C | 1 |
| Diehl, V | 1 |
| Josting, A | 1 |
| Sternberg, DW | 1 |
| Aird, W | 1 |
| Neuberg, D | 1 |
| Thompson, L | 1 |
| MacNeill, K | 1 |
| Amrein, P | 1 |
| Shulman, LN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase II Study of Mitoxantrone vs. Mitoxantrone With Cetuximab in Metastatic Androgen Independent Prostate Cancer (AIPC) Previously Treated With Docetaxel-based Chemotherapy[NCT00661492] | Phase 2 | 115 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Radiographic progression:~1) For bone scan, 2 unequivocal new lesions confirmed by a subsequent bone scan with at least 1 more new lesion; 2) Skeletal related event (eg, fracture, need for radiation to bone for pain, spinal cord compression, need for surgery to bone to prevent or treat a pathologic fracture)." (NCT00661492)
Timeframe: 24 months.
| Intervention | Probability of REPFS at 2-year (Number) |
|---|---|
| Arm 1 | 0.73 |
| Arm 2 | 0.80 |
OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date. (NCT00661492)
Timeframe: 30 months
| Intervention | months (Median) |
|---|---|
| Arm 1 | 11.9 |
| Arm 2 | 15.7 |
PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date. (NCT00661492)
Timeframe: 24 months
| Intervention | months (Median) |
|---|---|
| Arm 1 | 4.2 |
| Arm 2 | 5.5 |
TTP will be measured from the start of treatment date to the date the patient is first recorded as having disease progression (even in patients who discontinue study treatment early due to toxicity or death due to disease progression. (NCT00661492)
Timeframe: 24 months
| Intervention | Months (Median) |
|---|---|
| Arm 1 | 4.9 |
| Arm 2 | 6.6 |
Defined as the time from initiation of therapy until the first 25% increase from baseline in non-responders or 50% increase from nadir in responders as defined above. A minimum increase in the PSA of 5 ng/mL will be required for progression. (NCT00661492)
Timeframe: 24 months
| Intervention | Months (Median) |
|---|---|
| Arm 1 | 2.7 |
| Arm 2 | 2.7 |
ORR = CR + PR Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD. (NCT00661492)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 | 2.2 |
| Arm 2 | 3.8 |
PSA doubling time = [log (2)× t] ÷ [log (final PSA) - log (initial PSA)] (NCT00661492)
Timeframe: 24 months
| Intervention | months (Median) |
|---|---|
| Arm 1 | 2.3 |
| Arm 2 | 1.5 |
Defined as the fraction of patients with a ≥50% reduction in serum PSA confirmed by a second serum PSA at least 3 weeks later (NCT00661492)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 | 7.7 |
| Arm 2 | 17.6 |
1 trial available for mitoxantrone and Exanthema
| Article | Year |
|---|---|
Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2012 |
4 other studies available for mitoxantrone and Exanthema
| Article | Year |
|---|---|
A blueberry muffin rash at birth.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diagnosis, Differential; Exanthema; Huma | 2018 |
Congenital acute myeloid leukaemia with KMT2A rearrangement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Exanthema; Female; Gene Rearrangement; H | 2018 |
Extramedullary acute myeloid leukemia (granulocytic sarcoma) with arm paresis, maculopapular exanthema and organ involvement.
Topics: Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Arm; Biomarkers, Tumor; Carboxyl | 2003 |
Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Com | 2000 |